BillionToOne reported a surge in Q1 2026 revenue driven by increased prenatal and oncology-related clinical testing. The company posted $108.4 million in Q1 revenue, up 84% year over year, with prenatal testing accounting for $96.5 million and oncology testing revenue growing roughly fivefold to $10.7 million. The company said it accessioned 189,000 tests in the quarter, representing a 38% increase from Q1 2025. It also reiterated expectations that its Unity Confirm test could drive further differentiation after confirming high-risk results using circulating fetal cells isolated from maternal blood without invasive sampling. BillionToOne ended the quarter with $537.5 million in cash and raised full-year 2026 revenue guidance to $450 million–$465 million, underscoring the commercial traction of its prenatal testing platform as it expands confirmatory pathways.